Brokerages expect Charles River Laboratories International, Inc. (NYSE:CRL) to report $459.42 million in sales for the current quarter, Zacks reports. Eight analysts have issued estimates for Charles River Laboratories International’s earnings. The highest sales estimate is $471.00 million and the lowest is $454.50 million. Charles River Laboratories International posted sales of $425.72 million in the same quarter last year, which suggests a positive year over year growth rate of 7.9%. The firm is expected to announce its next earnings results before the market opens on Thursday, November 9th.

According to Zacks, analysts expect that Charles River Laboratories International will report full year sales of $459.42 million for the current year, with estimates ranging from $1.83 billion to $1.87 billion. For the next financial year, analysts anticipate that the firm will report sales of $1.98 billion per share, with estimates ranging from $1.96 billion to $2.01 billion. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that that provide coverage for Charles River Laboratories International.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, August 9th. The medical research company reported $1.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.22 by $0.07. Charles River Laboratories International had a net margin of 10.13% and a return on equity of 27.02%. The company had revenue of $469.13 million during the quarter, compared to analyst estimates of $458.25 million. During the same period last year, the firm posted $1.20 EPS. Charles River Laboratories International’s revenue for the quarter was up 8.1% compared to the same quarter last year.

Several equities research analysts have recently weighed in on CRL shares. Credit Suisse Group reissued a “neutral” rating and issued a $112.00 price objective (up from $95.00) on shares of Charles River Laboratories International in a report on Monday, October 16th. Jefferies Group LLC increased their price objective on Charles River Laboratories International from $120.00 to $130.00 and gave the company a “buy” rating in a report on Monday, October 9th. Robert W. Baird reissued a “buy” rating and issued a $114.00 price objective on shares of Charles River Laboratories International in a report on Friday, September 1st. Royal Bank Of Canada started coverage on Charles River Laboratories International in a report on Tuesday, September 19th. They issued a “sector perform” rating and a $110.00 price objective for the company. Finally, BidaskClub raised Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a report on Tuesday, August 22nd. Six research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $102.05.

In related news, insider William D. Barbo sold 4,000 shares of the stock in a transaction on Thursday, August 17th. The stock was sold at an average price of $99.91, for a total transaction of $399,640.00. Following the completion of the sale, the insider now directly owns 20,424 shares of the company’s stock, valued at $2,040,561.84. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider David Ross Smith sold 2,552 shares of the stock in a transaction on Monday, August 14th. The stock was sold at an average price of $67.10, for a total value of $171,239.20. Following the sale, the insider now directly owns 11,671 shares of the company’s stock, valued at $783,124.10. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 18,699 shares of company stock valued at $1,892,393. Corporate insiders own 2.20% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of CRL. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Charles River Laboratories International by 12.7% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,791 shares of the medical research company’s stock worth $181,000 after purchasing an additional 202 shares during the period. Riverhead Capital Management LLC lifted its holdings in shares of Charles River Laboratories International by 14.7% during the second quarter. Riverhead Capital Management LLC now owns 1,931 shares of the medical research company’s stock worth $195,000 after purchasing an additional 247 shares during the period. Cambridge Advisors Inc. acquired a new stake in shares of Charles River Laboratories International during the second quarter worth $202,000. Advisor Partners LLC acquired a new stake in shares of Charles River Laboratories International during the second quarter worth $208,000. Finally, Campbell & CO Investment Adviser LLC acquired a new stake in shares of Charles River Laboratories International during the second quarter worth $217,000. 95.08% of the stock is owned by hedge funds and other institutional investors.

Charles River Laboratories International (CRL) opened at 115.17 on Monday. Charles River Laboratories International has a 52-week low of $67.20 and a 52-week high of $115.96. The stock has a market capitalization of $5.48 billion, a price-to-earnings ratio of 30.35 and a beta of 0.96. The firm’s 50-day moving average is $109.24 and its 200-day moving average is $99.03.

ILLEGAL ACTIVITY WARNING: “$459.42 Million in Sales Expected for Charles River Laboratories International, Inc. (CRL) This Quarter” was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://www.americanbankingnews.com/2017/10/23/459-42-million-in-sales-expected-for-charles-river-laboratories-international-inc-crl-this-quarter.html.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Get a free copy of the Zacks research report on Charles River Laboratories International (CRL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.